Oncomed comes off its quiet period with a few upbeat initiations

Recent IPO OncoMed Pharmaceuticals (OMED-2%) slips today despite a few upbeat initiations by Wall Street firms:

Jefferies starts the shares with a Buy and a $27 price target, saying OMED is a leader in the science behind cancer stem cells, which are thought to drive progression and metastases, and has generated five clinical stage candidates in Phase 1 trials using its platform, which has created multiple opportunities for success in major solid tumors and hematologic malignancies.

Jefferies acted as lead bookrunner in the IPO In July.

Leerink Swann and BMO Capital also ramp up coverage with an Outperform, and Piper Jaffray with an Overweight.

From other sites
Comments (1)
  • rambler1
    , contributor
    Comments (977) | Send Message
    After the IPO over hype now its another show me biotech.
    12 Aug 2013, 03:45 PM Reply Like
DJIA (DIA) S&P 500 (SPY)
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs